Recommendation of Selvita S.A. project for co-funding under the FENGprogram

The Management Board of Selvita S.A., with its registered office inKrakow (the "Company" or the "Issuer"), hereby informs that it wasnotified that the project entitled "Development of DRUG-PREDICTtechnology for preclinical prediction of the clinical efficacy ofbiologically active compounds in colorectal and pancreatic cancerindications, based on translational in vitro and in vivo preclinicalmodels supported by an ML tool enabling the identification of the bestinnovative drug candidates and optimal patient groups" (the "Project")has been placed on the list of projects selected for co-funding underthe European Funds for a Modern Economy 2021-2027 Program, Measure 1.1FENG - SMART Path, organized by the National Centre for Research andDevelopment (pol. Narodowe Centrum Badań i Rozwoju). The Project will beimplemented in the years 2026-2029 in collaboration with theJagiellonian University Collegium Medicum ("JU CM").

The objective of the Project is to develop innovative solutionssupporting the preclinical discovery of oncology drugs in colorectal andpancreatic cancer. The Project will enable the refinement of in vitroand in vivo studies in order to more accurately predict the efficacy ofnew drug candidates in clinical trials, as well as to better identifypatient groups in which such therapies may demonstrate clinical benefit.The planned solution will integrate subsequent stages of acquisition,generation, and characterization of cell models derived from colorectaland pancreatic tumors, to be used for preclinical in vitro and in vivostudies, supported by a bioinformatics tool based on machine learningmethods for the interpretation of obtained results.

The total eligible (net) cost of the Project amounts to PLN 17,213,666,of which the co-funding constitutes PLN 12,920,962.83, including PLN6,671,247 for the Company and PLN 6,249,715 for JU CM.

The final amount of co-funding may be subject to minor adjustments atthe stage of preparing the documentation for the relevant grantagreement.

Disclaimer: This English language translation has been prepared solelyfor the convenience of English-speaking readers. Despite all the effortsdevoted to this translation, certain discrepancies, omissions, orapproximations may exist. In case of any differences between the Polishand the English versions, the Polish version shall prevail. SelvitaS.A., its representatives, and employees decline all responsibility inthis regard.